Category: by author

Not so fast! Journal retracts paper from Boldt group over author hijinks, more

We knew we hadn’t heard the last of Joachim Boldt, whose nearly 90 retractions make him the putative record holder for a single author in this indistinguished club. But we didn’t expect this:

The European Journal of Anaesthesiology has retracted a paper, “Supplemental oxygen reduces serotonin levels in plasma and platelets during colorectal surgery and reduces postoperative nausea and vomiting,” from Boldt’s former colleagues at the Klinikum Ludwigshafen after determining that the authors were trying to hide their association with the disgraced anesthesiologist.

Continue reading Not so fast! Journal retracts paper from Boldt group over author hijinks, more

Two mega-corrections for Anil Potti in the Journal of Clinical Oncology

Anil Potti can add two corrections to his less-and-less impressive publication record. The mega-corrections — part of what we are close to being ready to call a trend in errata notices — in the Journal of Clinical Oncology (JCO) are, however, quite impressive, each with at least a dozen points.

One of the corrections, for a paper cited 15 times, according to Thomson Scientific’s Web of Knowledge, basically removes all references to chemotherapy sensitivity: Continue reading Two mega-corrections for Anil Potti in the Journal of Clinical Oncology

MD Anderson researcher Aggarwal loses paper in Cancer Letters

Whether it’s a one-off or a sign of things to come, Bharat Aggarwal, the MD Anderson scientist at the center of a blogospheric storm—and an institutional investigation—over the validity of his data, has had a paper withdrawn by the journal Cancer Letters. Continue reading MD Anderson researcher Aggarwal loses paper in Cancer Letters

Anil Potti and colleagues retract ninth paper, this one in JCO

Former Duke oncology researcher Anil Potti has retracted another paper, marking his ninth withdrawal. The notice in the Journal of Clinical Oncology (JCO) reads:

“An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer” by Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, Regina S. Whitaker, LiHua Li, Jonathan Gray, Jeffrey Marks, Geoffrey S. Ginsburg, Anil Potti, Mike West, Joseph R. Nevins, and Johnathan M. Lancaster (J Clin Oncol 25:517-525, 2007)

The majority of the authors wish to retract this article because Continue reading Anil Potti and colleagues retract ninth paper, this one in JCO

MD Anderson investigating researcher Bharat Aggarwal over images

Bharat Aggarwal, an influential MD Anderson researcher who has been accused in the blogosphere of manipulating images in a slew of published studies, acknowledged to Retraction Watch that the Houston institution is investigating the matter. Reached by Retraction Watch by phone at his office, Aggarwal said MD Anderson

has been looking into it and I think that they will tell everybody what it is all about. I think that somebody out there is putting this whole thing together and their mind is made up.

However, Aggarwal, chief of the center’s cytokine research section, denied that any retractions of his papers were forthcoming. He refused to comment on whether officials had confiscated his computer, as a commenter to this blog has claimed. Continue reading MD Anderson investigating researcher Bharat Aggarwal over images

Second retraction for former SUNY Upstate department chair found guilty of misconduct

Last week, we covered the case of Michael W. Miller, a former department chair at the State University of New York (SUNY) Upstate who was forced to retract a paper in the Journal of Neurochemistry after a university investigation found he had committed misconduct.

We figured more retractions might be on the way, so we weren’t surprised when a commenter informed us earlier today of “very interesting and odd retraction letter.” Miller has had at least one other retraction, it turns out, this one in Developmental Neuroscience for 2009’s “Lability of Neuronal Lineage Decisions Is Revealed by Acute Exposures to Ethanol.” Here’s the notice, published online on January 19: Continue reading Second retraction for former SUNY Upstate department chair found guilty of misconduct

Resveratrol researcher Dipak Das: My lab’s work was “99% correct”

Das, via UConn

Dipak Das, the UConn red wine researcher charged by his institution with rampant misconduct that will likely lead to dozens of retractions, is evidently a 99%-er — when it comes to accuracy, that is.

According to a statement purportedly from his lawyer refuting those charges, Das claims, among other things, that the output from his lab was nearly perfect. He also has a lot to say about a 60,000-page report that the statement says he may not have actually downloaded.

We might note a lot more things about the letter, which we received from Bill Sardi, president of Longevinex, a resveratrol company which has worked with Das. Sardi has been sending Das defenses since the story broke; we posted some of them and Derek Lowe has posted parts of another. But here’s the letter, in its entirety: Continue reading Resveratrol researcher Dipak Das: My lab’s work was “99% correct”

Journal of Neurochemistry retracts paper after SUNY Upstate medical school finds evidence of fraud

Following an investigation by the State University of New York (SUNY) Upstate into the work of one of its neuroscientists, the Journal of Neurochemistry has retracted a 2007 paper.

The retraction notice is quite clear about why the paper is being withdrawn: Continue reading Journal of Neurochemistry retracts paper after SUNY Upstate medical school finds evidence of fraud

So how peripheral was Dipak Das’ resveratrol work, really?

In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”

Harvard’s David Sinclair went further, telling The New York Times that he didn’t know who Das was: Continue reading So how peripheral was Dipak Das’ resveratrol work, really?

Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges

Das, via UConn

Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.

First, we have confirmed with publisher Mary Ann Liebert this morning that Das has been relieved of his duties as co-editor in chief of Antioxidants & Redox Signaling. He had shared that post with Chandan Sen, and his name as been removed from the masthead of that journal. Here’s a statement from the publisher: Continue reading Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges